/ALT
ALT Stock - Altimmune, Inc.
Healthcare|BiotechnologyNASDAQ
$3.90-22.77%
$1.15 (-22.77%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.12
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+617.9%upside
Target: $28.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.86 – $3.94
TARGET (TP)$28.00
STOP LOSS$3.59
RISK/REWARD1:77.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.04
52W High$8.25
52W Low$2.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $20,000 | $426,000 | $-68,000 | $4.41M | $8.19M |
| Gross Profit | $20,000 | $426,000 | $-68,000 | $4.41M | $-25,324,291 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -309.4% |
| Operating Income | $-103,172,000 | $-95,929,000 | $-87,740,000 | $-96,914,000 | $-54,798,741 |
| Net Income | $-95,059,000 | $-88,447,000 | $-84,713,000 | $-97,090,000 | $-49,044,477 |
| Net Margin | -475295.0% | -20762.2% | 124577.9% | -2201.6% | -599.2% |
| EPS | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 |
Company Overview
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
43%
Hold / Neutral
3
43%
Sell / Underperform
1
14%
Analyst Consensus🔴 Bearish
3 Bullish4 Neutral/Bearish
Price Targets
$14
Average Target
↑ 259.0% Upside
Now
$1
Low
$14
Average
$26
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 10th 2025 | Goldman | Resumed | Sell | $1 |
| February 28th 2025 | William Blair | Initiation | Market Perform | - |
| January 8th 2025 | Stifel | Initiation | Buy | $18 |
| November 12th 2024 | UBS | Initiation | Buy | $26 |
| April 29th 2024 | Guggenheim | Downgrade | Neutral | - |
| January 24th 2024 | Goldman | Initiation | Neutral | $13 |
| March 22nd 2023 | Goldman | Downgrade | Neutral | $6← $20 |
| December 1st 2022 | Goldman | Initiation | Buy | $20 |
Earnings History & Surprises
ALTBeat Rate
89%
Last 18 quarters
Avg Surprise
+5.3%
EPS vs Estimate
Beats / Misses
16/2
Last 12 quarters
Latest EPS
$-0.21
Q4 2025
EPS Surprise History
Q1 24
+5.7%
$-0.33vs$-0.35
Q2 24
+5.6%
$-0.34vs$-0.36
Q3 24
-2.9%
$-0.35vs$-0.34
Q4 24
+11.1%
$-0.32vs$-0.36
Q1 25
+2.9%
$-0.33vs$-0.34
Q2 25
+25.7%
$-0.26vs$-0.35
Q3 25
+15.6%
$-0.27vs$-0.32
Q4 25
+27.6%
$-0.21vs$-0.29
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.25 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.29 | $-0.21 | +27.6% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.32 | $-0.27 | +15.6% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.35 | $-0.26 | +25.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.34 | $-0.33 | +2.9% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.34 | $-0.35 | -2.9% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.36 | $-0.34 | +5.6% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-0.35 | $-0.33 | +5.7% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.40 | $-0.39 | +2.5% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.44 | $-0.32 | +27.3% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.49 | $-0.40 | +18.4% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.52 | $-0.43 | +17.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.49 | $-0.48 | +2.0% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.45 | $-0.42 | +6.7% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.57 | $-0.44 | +22.8% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-0.64 | $-0.49 | +23.4% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.36 | $-0.81 | -125.0% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.44 | $-0.40 | +9.1% | ✓ BEAT |
Latest News
Altimmune shares are trading lower. The company announced topline results from the IMPACT Phase 2b trial of Pemvidutide that showed improvement in antifibrotic activity with both treatment doses.
📉 NegativeBenzinga•Dec 19, 2025, 08:19 PM
Altimmune's Topline Results From IMPACT Phase 2b Trial Of Pemvidutide For Metabolic Dysfunction-Associated Steatohepatitis Showed Improvement In Antifibrotic Activity With Both Treatment Doses
📈 PositiveBenzinga•Dec 19, 2025, 11:32 AM
Altimmune Announces CEO Transition As Jerry Durso Succeeds Vipin Garg To Lead Next Phase Of Growth
📈 PositiveBenzinga•Dec 1, 2025, 12:41 PM
Altimmune Announces Publication In The Lancet Of 24-Week Efficacy And Safety Data From Ongoing IMPACT Phase 2b Trial Of Pemvidutide In Patients With MASH
📈 PositiveBenzinga•Nov 11, 2025, 01:53 PM
Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $14
➖ NeutralBenzinga•Nov 7, 2025, 01:37 PM
Altimmune Data From AI-Based Analysis Of Biopsies From IMPACT Phase 2b Trial Of Pemvidutide Demonstrates Reductions In Proportionate Areas Of Early, Advanced And Total Liver FibrosisAt 24 Weeks
📈 PositiveBenzinga•Nov 7, 2025, 01:14 PM
Altimmune Q3 EPS $(0.21) Beats $(0.27) Estimate, Sales $5.000K Beat $1.250K Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:07 PM
Altimmune Completes Patient Enrollment In RECLAIM, Phase 2 Clinical Trial Evaluating Pemvidutide In Adults With Alcohol Use Disorder
📈 PositiveBenzinga•Nov 3, 2025, 12:37 PM
HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 11:59 AM
Altimmune To Present 24-Week Data From Phase 2b IMPACT Trial Of Pemvidutide In Metabolic Dysfunction-Associated Steatohepatitis At The Liver Meeting 2025
➖ NeutralBenzinga•Oct 20, 2025, 11:36 AM
HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
📈 PositiveBenzinga•Oct 10, 2025, 11:04 AM
Altimmune Announces Pemvidutide As The Only Drug Granted Fast Track Designation In Alcohol Use Disorder With Phase 2 RECLAIM Study Ongoing
📈 PositiveBenzinga•Aug 19, 2025, 11:33 AM
Altimmune stock rises on promising Q2 report
📈 PositiveSeeking Alpha•Aug 12, 2025, 05:22 PM
Madrigal, Viking among notable gainers after Altimmune's MASH setback
📈 PositiveSeeking Alpha•Jun 26, 2025, 07:42 PM
Altimmune plunges after mid-stage trial data for MASH therapy
📉 NegativeSeeking Alpha•Jun 26, 2025, 11:57 AM
Frequently Asked Questions about ALT
What is ALT's current stock price?
Altimmune, Inc. (ALT) is currently trading at $3.90 per share. The stock has moved -22.77% today.
What is the analyst price target for ALT?
The average analyst price target for ALT is $28.00, based on 1 analyst.
What sector is Altimmune, Inc. in?
Altimmune, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALT's market cap?
Altimmune, Inc. has a market capitalization of $0.34 billion, making it a small-cap company.
Does ALT pay dividends?
No, Altimmune, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
AURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
DBVT
DBV Technologies S.A.
$22.76
Mkt Cap: $0.5B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
Explore stocks similar to ALT for comparison